key: cord-0253070-9ex61dl5
authors: Lin, Jonah; Law, Ryan; Korosec, Chapin S.; Zhou, Christine; Koh, Wan Hon; Ghaemi, Mohammad Sajjad; Samaan, Philip; Ooi, Hsu Kiang; Yue, FengYun; Gingras, Anne-Claude; Estacio, Antonio; Buchholz, Megan; Cheatley, Patti Lou; Pavinski, Katerina; Mubareka, Samira; McGeer, Allison J.; Leis, Jerome A.; Heffernan, Jane M.; Ostrowski, Mario
title: Longitudinal Assessment of SARS-CoV-2 Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multi-Cytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity
date: 2022-01-20
journal: bioRxiv
DOI: 10.1101/2022.01.18.476864
sha: 9a1b036ba645a7143276e2d0228321acebda3dfc
doc_id: 253070
cord_uid: 9ex61dl5

Cellular-mediated immunity is critical for long-term protection against most viral infections, including coronaviruses. We studied 23 SARS-CoV-2-infected survivors over a one year post symptom onset (PSO) interval by ex vivo cytokine ELISpot assay. All subjects demonstrated SARS-CoV-2-specific IFN-γ, IL-2, and Granzyme B (GzmB) T cell responses at presentation, with greater frequencies in severe disease. Cytokines, mainly produced by CD4+ T cells, targeted all structural proteins (Nucleocapsid, Membrane, Spike) except Envelope, with GzmB > IL-2 > IFN-γ. Mathematical modeling predicted that: 1) cytokine responses peaked at 6 days for IFN-γ, 36 days for IL-2, and 7 days for GzmB, 2) severe illness was associated with reduced IFN-γ and GzmB, but increased IL-2 production rates, 3) males displayed greater production of IFN-γ, whereas females produced more GzmB. Ex vivo responses declined over time with persistence of IL-2 in 86% and of IFN-γ and GzmB in 70% of subjects at a median of 336 days PSO. The average half-life of SARS-CoV-2-specific cytokine-producing cells was modelled to be 139 days (∼4.6 months). Potent T cell proliferative responses persisted throughout observation, were CD4 dominant, and were capable of producing all 3 cytokines. Several immunodominant CD4 and CD8 epitopes identified in this study were shared by seasonal coronaviruses or SARS-CoV-1 in the Nucleocapsid and Membrane regions. Both SARS-CoV-2-specific CD4+ and CD8+ T cell clones were able to kill target cells, though CD8 tended to be more potent. Importance Our findings highlight the relative importance of SARS-CoV-2-specific GzmB-producing T cell responses in SARS-CoV-2 control, shared CD4 and CD8 immunodominant epitopes in seasonal coronaviruses or SARS-CoV-1, and indicate robust persistence of T cell memory at least one year after infection. Our findings should inform future strategies to induce T cell vaccines against SARS-CoV-2 and other coronaviruses.

IL-2 in 86% and of IFN-γ and GzmB in 70% of subjects at a median of 336 days PSO. The average 48 half-life of SARS-CoV-2-specific cytokine-producing cells was modelled to be 139 days (~4.6 49 months). Potent T cell proliferative responses persisted throughout observation, were CD4 50 dominant, and were capable of producing all 3 cytokines. Several immunodominant CD4 and CD8 51 epitopes identified in this study were shared by seasonal coronaviruses or SARS-CoV-1 in the 52 Nucleocapsid and Membrane regions. Both SARS-CoV-2-specific CD4+ and CD8+ T cell clones 53 were able to kill target cells, though CD8 tended to be more potent. 54 vaccines, given the emergence of antibody escape variants in vaccinated persons. It is still unclear 87 how long T cell memory can persist in SARS-CoV-2 infection, given that re-infection is very 88 common with coronaviruses in general (15, 16) , albeit often with reduced severity. Such 89 information should in the future reveal how T cells operate as correlates of protection against 90 infection and disease. 91

In the current study, we prospectively followed a cohort of SARS-CoV-2 infected individuals with 93 varying levels of disease outcome by using highly sensitive cytokine ELISpot assays to follow 94 SARS-CoV-2 antigen-specific cytokine responses averaging about one year of follow up. We 95 modelled the kinetics of the T cell cytokine response with time. In addition, we mapped a panel of 96 epitopes to structural proteins that characterized dominant T cell responses in this cohort and show 97 effector function and killing capabilities of both CD4+ and CD8+ T cell clones. 98 resuspended in R10-Max media that contains 2 mM Glutamax instead (Gibco). T cells were plated 168 in 96-well plates at limiting dilution. T cells were then co-cultured with irradiated feeder cells 169 containing allogeneic PBMC and BCL, 50 U/mL IL-2 (R&D Systems), 10 ng/mL Systems), and 25 ng/mL mouse anti-human CD3 antibody (UCHT1; BD Bioscience). T cells were 171 incubated at 37°C for 4-5 weeks and fed biweekly with R10-Max and 50 U/mL IL-2. Next, ELISpot was used to screen the potential T cell clones for specificity against the peptide of interest 173

(1 μg/mL) in the presence of autologous BCL (1 x 10 3 cells/well). For T cell lines, PBMCs were 174 pulsed with 50 µg/mL of the target peptide for 1 hour at 37°C, diluted to 1 µg/mL of peptide, and 175 plated in 12-well plates at 2 x 10 6 cells/mL. After 24 hours incubation at 37°C, 50 U/mL IL-2, and 176 25 ng/mL IL-7 were added. PBMCs were kept in culture for 3-5 weeks and stimulated weekly with 177 1 µg/mL of target peptide, 50 U/mL IL-2, and 25 ng/mL IL-7. IFN-γ ELISpot was then used to 178 test the specificity of potential T cell lines against the target peptide (1 μg/mL) in the presence of 179 autologous BCL (1 x 10 3 cells/well). The T cell compositions of clones and lines that elicited 180 positive IFN-γ ELISpot responses were then examined via flow cytometry. 181

To determine HLA I-restricted epitopes from CD8+ T cells, a B cell panel containing autologous 184 and allogeneic BCL was used. BCL were pulsed with the specific peptide for 1 hour at 10 µg/mL, 185 washed, then co-cultured with CD8+ T cell clones in an IFN-γ ELISpot. To determine HLA II-186 restricted epitopes from CD4+ T cell clones or lines, autologous BCL were blocked with 10 µg/mL 187 of either anti-HLA-A/B/C (BD Biosciences), anti-HLA-DP (Abcam), anti-HLA-DQ (BioLegend), 188

anti-HLA-DR (BioLegend), or anti-HLA-DP/DQ/DR (BioLegend) antibodies for 30 minutes, then 189 pulsed with the specific peptide for 1 hour at 10 µg/mL. Pulsed BCL (1 x 10 3 cells/well) were then 190 washed 3 times with R10, mixed with CD4+ T cells (1-2 x 10 4 cells/well), and tested in ELISpot assay in the presence of 10 µg/mL of anti-HLA antibodies. 192

CFSE T cell proliferation assay was performed as previously described (20) warm R10 prior to mixing at 1:1 ratio and resuspended to 2 x 10 5 cells/mL for plating. For effector 223 cells, T cell clones were washed three times with warm R10 to remove any excess cytokines and 224 serially diluted from 32:1 to 0.5:1 (Effector:Target Ratio). Both target and effector cells were then 225 plated to 96-well U-bottom plate and incubated for 6 hours at 37°C. Cells were then stained with 226 LIVE/DEAD™ fixable near IR cell stain (Thermo Fisher Scientific) and incubated with Fc 227 receptor blocking solution (Human TruStain FcX TM ; BioLegend) before surface staining with 228 fluorochrome-conjugated antibodies to CD4 (BV711: Clone SK3) and CD8 (PE: Clone HIT8a). 229

In a separate experiment, intracellular cytokines secreted by the T cells clones were determined as 230 previously described by using anti-IFN-γ (APC: Clone 4S.B3), and anti-GzmB (BV421: Clone 231 GB11. All antibodies were purchased from BD Bioscience. Samples were then acquired on the 232 BD LSR Fortessa. 

All fits to clinical data using our model (Equation 1) were performed in Monolix (Version 2020R1) 248 using non-linear mixed-effects models. Individual parameters (Tables S2 and S3) for each data 249 set are determined by the maximum likelihood estimator Stochastic Approximation Expectation-250 Maximization (SAEM), and all fits met the standard convergence criteria (complete likelihood 251 estimator). As shown in Table S2 , many parameters from Eq.1 are fit for this study. However, 252 parameters from Eq.1a-d are chosen based on previous studies on SARS-CoV-2. 253

Clinical data of SARS-CoV-2 infected subjects can be found in Table 1 . 23 subjects were sampled 257 at the time of presentation, either during acute infection and/or shortly after convalescence, ranging 258 between 7-160 days post symptom onset (PSO). However, only 21 subjects were available for 259 subsequent blood draws to understand long-term persistence of immune memory to SARS-CoV-260 2 (2-7 blood draws up to 398 days PSO). All subjects were infected with the ancestral circulating 261

Wuhan strain. Disease severity ranged from mild (non-hospitalized), moderate (hospitalized not 262 ICU) to severe (ICU admission). Out of the 23 subjects studied, 9 were female (39%) and 14 were 263 male (61%), with an average age of 50 ranging from 23-72 years; 14 had mild (61%), 6 had 264 moderate (26%), and 3 had severe (13%) COVID-19 disease. Two subjects (OM8100 and 265 OM8123) received one dose of the Pfizer BNT162b2 COVID-19 mRNA vaccine in between study 266 visits. Another subject (OM8126) received two doses of the Pfizer vaccine in between study visits. 267

Healthy controls subjects included individuals who had blood drawn either pre-COVID (before 268 January 2020) or were asymptomatic with no history of viral illness and had negative SARS-CoV-269 2 serology. Three individuals who were hospitalized were sampled intensively at 7-10 day 270 intervals during and after their hospital admission for 6 weeks. The remainder of individuals were 271 sampled during their convalescence after most symptoms had resolved. 272 273

Effector T cell responses that include IFN-γ (25), IL-2 (26), and GzmB (27) production are 275 important in viral control of a Th1-mediated anti-viral response. Cytokine ELISpot assay is a 276 highly sensitive methodology to detect low frequency viral antigen-specific responses in ex vivo PBMC during or after virus infections (28). We measured SARS-CoV-2 antigen-specific IFN-γ, 278 IL-2, and GzmB responses at presentation by cytokine ELISpot assay. We measured responses to 279 the structural proteins of SARS-CoV-2 that included Spike (S1 and S2), Membrane (M), 280

Nucleocapsid (N), and Envelope (E) (Figure 1a ). In addition, we included a peptide pool only 281 spanning Spike receptor binding domain and transmembrane domains (S-RBD and S-TM) Although all three individuals had moderate disease and were discharged from hospital, we find 293 considerable dynamic fluctuations in their early T cell cytokine responses to SARS-CoV-2 294

antigens. Cytokine antigen-specific responses were detectable at all time points. We tended to see 295 an early peak of T cell cytokine responses in the first 22-28 days, followed by a leveling of the 296 response afterwards. 297 298

To examine the duration and the strength of the T cell responses against SARS-CoV-2 structural 300 proteins (N, E, M, S1 -5' region of spike with RBD, S2 -3' region of spike after RBD), 21 301 convalescent (most symptoms resolved) subjects (13 Mild, 6 Moderate, and 2 Severe) were 302 examined longitudinally via ex vivo cytokine ELISpot, where the median time days PSO of first 303 blood draw was 38 days (range 7-160 days PSO). In the majority of subjects, the first time point 304 sampled we usually observed the most potent cytokine responses. A summary of all cytokine 305 responses of all individuals during their maximal response during convalescence is depicted in 306 Figure 2 . As for the most frequent T cell targets of SARS-CoV-2 structural proteins, 7/21 (33%) 307 subjects responded to N most frequently, followed by S2 with 6/21 (29%) subjects, S1 with 5/21 308 (24%) subjects, and M with 4/21 (19%) subjects. No responses to E protein were observed. The 309 greatest frequency of cytokine producing cells were found in those with moderate and severe 310 disease compared to mild disease. Total ex vivo SARS-CoV-2-specific frequencies for 311 severe/moderate disease subjects versus mild disease were for IFN-γ, 852 versus 204 SFC/10 6 312 PBMC (p = 0.02), for IL-2, 1358 versus 191 SFC/10 6 PBMC (p < 0.001), and for GzmB, 1030 313 versus 331 SFC/10 6 PBMC (p = 0.023), respectively; thus, indicating that those with 314 severe/moderate disease had higher frequencies of cytokine-producing SARS-CoV-2-specific T 315 cells than those who suffered mild disease during convalescence. Overall, GzmB cytokine 316 responses from ex vivo T cells were greater than IL-2, which were greater than IFN-γ. Among the 317 21 participants, 11 exhibited GzmB responses as their strongest cytokine response, which were 318 against mainly N and S1/S2. 7 participants possessed IL-2 responses as their strongest response, 319 which were mainly against M and S1/S2. Only 3 subjects exhibited IFN-γ as their strongest 320 responses, which targeted mainly N and S1/S2. The majority of the cytokine response was 321 contributed by CD4+ T cells, since CD4+ T cell depletion of PBMC resulted in reduction of all cytokine responses by 90% (range 70-95%, see Supplemental Figure S1 , and data not shown). In 323 order to further understand the intensity of SARS-CoV-2-specific T cell responses in convalescent 324 individuals, we also looked at uninfected individuals (pre-2020 and asymptomatic SARS-CoV-2 325 seronegative individuals) since pre-existing immunity to seasonal alpha and beta coronaviruses 326 may impart cross-reactive immune responses to SARS-CoV-2 antigens, as recently demonstrated 327 (12, 29, 30) . We find that at least 50% of uninfected and pre-COVID-19 individuals can 328 demonstrate cross-reactive immune responses to SARS-CoV-2 proteins, (Supplemental Figure  329 S2), with 6/11 SARS-CoV-2 negative individuals having detectable IFN-γ responses, which were 330 generally observed at lower frequencies than convalescent individuals. 331

We followed ex vivo cytokine responses over a one year period (range 169 to 398 days PSO). In 333 general, we saw a decline in ex vivo SARS-CoV-2 responses to all antigens and cytokines. A 334 representative example of one individual is shown in Figure 3 . To understand the decay of immune 335 memory, the frequency of low-level SARS-CoV-2 ex vivo responses that declined to below 50 336 SFC/10 6 PBMC to all antigens combined (N, E, M, and S1 + S2) was 33% for IFN-γ, 14% for IL-337 2, and 29% for GzmB at a median time point of 336 days PSO. Three individuals also received 338

BNT162b2 vaccine during follow-up and showed variable ELISpot responses post vaccination: 339 one subject (OM8100) showed increased IFN-γ/IL-2/GzmB responses to Spike (S1 + S2), but 340 continued decay of N, M after vaccination; the second subject (OM8123) showed continued decay 341 of responses after vaccination; the third subject (OM8126) showed only increased IFN-γ responses 342 only to S1 but no changes against other proteins (data not shown). 343 344

Using a within-host model (Eq.1), individual fit parameters for the period of data collection for 21 346 participants are shown for total SARS-CoV-2 IFN-γ/IL-2/GzmB responses in Figure 4 . The model 347 predicted that the immune response variables peaked at 6 days for IFN-γ, 36 days for IL-2, and 7 348 days for GzmB. Thus, IFN-γ and GzmB appeared to peak earlier than IL-2. Our model, based on 349 severity of disease, is shown in Figure 5 detailing the average case-severity predicted responses 350 for disease severity as a function of time. For each immune response variable and for each disease 351 severity, we predicted the average response out to two years PSO. We find that the IFN- response 352

to have the highest peak for severe cases with a value of ~100 SFC/10 6 , followed by moderate 353 (~90 SFC/10 6 ), and then mild (~31 SFC/10 6 ). For IL-2, all case severities peak at the same time, 354 however, severe cases display a peak response twice that of moderate, and moderate disease 355 displays a peak response four-fold higher than compared to mild cases. In contrast, GzmB displays 356 little qualitative severity dependence. We then looked at average cytokine production and 357 degradation rates with disease severity (Figure 5 d-i) . The model predicts that severe illness is 358 associated with a reduced IFN-γ and GzmB, but increased IL-2 production rates (Figure 5 d, e, f) . 359

For instance, mean IL-2 production (μΙΤ) is found to be 0.0066±0.0010 d -1 , 0.00685±0.001 d -1 , and 360 0.00891±0.00123 d -1 , for mild, moderate and severe disease, respectively (Figure 5 e). Mean IL-361 2 degradation (γ1) is found to be 0.107089±0.015004 d -1 , 0.0983±0.01608 d -1 , and 0.0728±0.01303 362 d -1 , for mild, moderate and severe, disease respectively. Mean GzmB production was found to be 363 0.2632±0.117 d -1 , 0.1623±0.0915 d -1 , and 0.115±0.0517 d -1 , for mild, moderate and severe disease, 364 respectively. We also applied our model based on sex Figure 6 . We find that for IFN-γ, males 365 display faster stimulation and slower degradation rates compared to females, whereas for GzmB, 366 we find that females display faster stimulation and slower degradation than males. For IL-2, 367 stimulation and degradation rates are similar between males and females. 368 in Figure 8 and summary data are shown in Table 2 . In some individuals, a substantial frequency 404 of epitope-specific IFN-γ responses could be detected ex vivo, varying from 20 SFC/10 6 upward 405 to ≥4000 SFC/10 6 . As shown in Table 2 , we were able to define a total of 35 epitopes that belong 406 to ORF1ab (1 epitope), N (13 epitopes), M (14 epitopes), and S (7 epitopes). Shorter amino acid 407 epitopes were not included in the total count since they overlap with the longer amino acid 408 epitopes. Epitopes from M elicited the strongest response in terms of breadth and frequencies in 409 ex vivo PBMC, followed by N, S, and ORF1ab. However, we could not fully characterize the S 410 protein epitopes due to unavailability of full S protein peptide matrices at the time of 411 experimentation. Interestingly, no responses to E were observed. Overall, the majority of epitopes 412 that we could define favoured CD4+ T cell responses over CD8+ T cell responses, with greater 413 breadth in individuals with more severe disease ( Table 2) . Many of the epitopes we identified 414 were previously identified by others (13, 32-51), suggesting common induction of certain epitopes 415 (see Table 2 ). These included one in the ORF1ab region, the alpha and beta coronavirus families 416 cross-reactive N26-N27 region, the N76-N88 region, the M154-156 region, and the M160-163 417 region ( Table 2 ). Of note is that N26-N27 region was also observed to be cross-reactive in SARS-418

CoV-1 and the other common cold coronaviruses (HKU1, OC43, NL63, 229E). The remaining 419 regions (N76-88, M154-156, and M160-163) were characterized in SARS-CoV-1 only. Nine 420 additional epitopes that were not studied as extensively have been further characterized in this 421 study ( Table 2) . We isolated two CD4+ T cell clones from one individual (OM8086). One clone 422 specific for M155 (LRGHLRIAGHHLGRC) was mainly restricted to HLA-DR, although some 423 inhibition (~40%) was observed in the presence of anti-HLA-DQ antibodies (Figure 9 ), suggesting 424 some promiscuity of this epitope. The other SARS-COV-2 CD4+ T cell clone specific for M156 425 (LRIAGHHLGRCDIKD) was restricted to HLA-DR only (Figure 9 ). Our findings for M155 and 426 M156 were consistent with previous studies (12, 13, 36, 43, 48, 52) . Specifically, two studies have 427 demonstrated that M155 and M156 were mainly restricted by HLA-DRB1*11, which 428 corresponded to the HLA of our subjects (36, 43) (Supplemental Table S1 ). Among the various 429

ORF1ab peptides tested, a response to TTDPSFLGRY was easily detected in 33% of individuals 430

and was determined to be HLA-A*01:01-restricted after testing with a panel of B cell lines ( Figure  431 9 c). This immunodominant epitope and HLA-restriction was previously reported in other studies 432 (32-35). We isolated a CD8+ T cell clone from one individual recognizing an epitope in the M 433 region, RNRFLYIIK (M128-6), that was restricted to HLA-A*30:01 (Figure 9) . Only in silico 434 analyses were conducted for this particular sequence and HLA restriction (47). However, no 435 responses against RNRFLYIIK were observed in two other HLA-A*30:01 patients in our cohort 436 (data not shown). Interestingly, another study had characterized a similar epitope shifted by one amino acid, NRFLYIIKL, to be restricted to HLA-C*07 (34). However, no responses against 438 NRFLYIIKL were detected in three of our HLA-C*07+ subjects (data not shown). Although 4/9 439 of our subjects that were screened for epitope mapping were HLA-A*02:01 restricted, we could 440 not detect any CD8+ T cell responses that were restricted to this common allele. 441

Both SARS-CoV-2-specific CD4+ and CD8+ T cell clones were able to kill peptide-pulsed 444 autologous B cell line target cells (Figure 10 a, b, c) . Interestingly, SARS-CoV-2 CD8+ T cell 445 clones tended to have enhanced cytotoxic capabilities compared to the SARS-CoV-2 CD4+ T cell 446 clones since they could kill at lower effector:target cell ratios (Figure 10 b, c) . Both CD4+ and 447

peptide of interest (Figure 10 d, e) . 449

The establishment of cellular-mediated immunity is critical against long lasting immunity against 451 most viral infections including coronaviruses. After SARS-CoV-1 infection, antibody-mediated 452 immunity was seen to wane over time (53, 54) , however, SARS-CoV-1-specific memory T cells 453

were observed to persist for 6 to 11 years post-infection in several studies, which were at higher 454 frequencies in those with more severe illness (39, 42, 53, 54) . In this study, we characterized 455 cytokine producing T cell responses to SARS-CoV-2 structural proteins during acute infection and 456

found potent Th1-focused pluri-cytokine producing responses early and during convalescence in 457 SARS-CoV-2 survivors, with frequencies ranging from 100 to over a 1000 cytokine producing 458 cells per 10 6 PBMC. These frequencies are similar to those reported by Le Bert et. al. (12) who 459

reported IFN-γ ELISpot against N in SARS-CoV-2 infected individuals. Our data expands these 460 findings to include IL-2, GzmB, and IFN-γ toward all structural proteins. It should be noted that 461 previous estimates describing SARS-CoV-2-specific T cells measured higher frequencies of 462 antigen-specific cells when using ex vivo flow cytometric techniques based on activation marker 463 upregulation when exposed to peptide pools (14, 29, 55) . However, these frequencies may not 

though it was observed for SARS- 54, 55, 57) . The reasons for this are currently, 474 unclear, although a recent study suggests that SARS-CoV-2 ORF8 protein may interfere with 475 MHC class I presentation, thus possibly preventing conventional CD8+ T cell priming (58). 476

Our data showed a number of features of the kinetics of SARS-CoV-2 T cell immunity. The 478 mathematical modelling results showed early induction of the effector cytokines IFN-γ and GzmB, 479 followed by IL-2 later which is consistent with the effector role of IFN-γ/GzmB in viral clearance 480 and IL-2 to induce long-term memory. Modelling also showed that disease severity induces greater 481 IFN-γ/IL-2, consistent with increased antigen load during moderate and severe disease. The similar 482 production and decay rates of GzmB in mild disease suggests that GzmB may have greater 483

importance at viral clearance, resulting in milder disease course. Our decay rates of T cell cytokine 484 responses were similar to those of Dan et. al. (14) , where they observed a half life decay of 3-5 485 months and we predicted 4.6 months. Our modeling studies also indicated that males and females 486 may differ in IFN- and GzmB production in median and variance during infection. Whether these 487 findings help explain the increased mortality rates in men over women to COVID-19 illness will 488 require further study (59, 60). We followed our cohort for at least one year, and encouragingly still 489 find persistence of T cell immunity in the majority of individuals, in particular, SARS-CoV-2-490 specific IL-2 in 86% and IFN-γ/GzmB in about 70%. Importantly, we were able to find potent 491 proliferative T cell responses that produce cytokines even at the last time points in all individuals 492 studied. These findings indicate that although decay of T cell immunity is observed over one year, 493 one can still induce potent proliferative and effector cytokine responses in T cell obtained one year 494 after infection in most, if not all individuals after restimulation. The role that these responses play 495 in protection against infection and/or disease will require further study and follow up. 496 497 SARS-CoV-2 T cell epitope discovery will inform future T cell-based coronavirus vaccines, 498 particularly in the setting of antibody escape variants. Several putative epitopes found in SARS-499

CoV-1 were, interestingly, observed in SARS-CoV-2. Specifically, the identification of similar 500 epitopes in the N26-N27, N76-N88, and M154-M163 regions in both SARS-CoV-1 and SARS-501

CoV-2, and other coronavirus families suggest that the common induction of certain epitopes 502 across coronavirus families could be used for vaccine development. We have also described a 503 number of new epitopes that could be incorporated in T cell vaccine designs. For example, the 504 M128-6 epitope (RNRFLYIIK) was a CD8+ HLA*30:01 restricted epitope. In addition, we 505 observed cross-reactive T cell responses in a large number of uninfected individuals which likely 506 reflect previous infection with seasonal coronaviruses. Recent work suggests that these cross-507 reactive responses may be important in alleviating, rather than exacerbating disease caused by 508 SARS-CoV-2 (61). The identification of additional, novel immunodominant epitopes, such as 509 M128-6 and M141, and the demonstration of recognition and cytotoxic capabilities of CD8+ and 510 CD4+ T cell clones in the M region will be critical for next generation vaccines against potential 511

Spike antibody escape variants. Of the epitopes induced on our subjects, a few mutations are 512 observed in the omicron variant (A63T for peptide M133, and del of 31 for peptide N5 in BA.1, 513 and S371F for peptide S170 in BA.2, see Table 2 ). Further work will determine if these mutations 514 confer escape from the T cell responses. Despite evading CD8+ T cell response induction, we find 515 that CD4+ T cell clones can kill peptide-pulsed target cells, albeit at seemingly lower 516 effector:target cell ratios than the CD8+ T cell clones that we isolated. These features may reflect one reason why SARS-CoV-2 can induce severe disease in a subset of individuals. A combination 518 of a poor CD8 + T cell response, with greater killing capacity and an over-exuberant CD4 + T cell 519 responses may contribute to disease severity. Thus, further studies will be needed to determine the 520 relative functional avidity of CD4+ vs CD8+ T cells targeting SARS-CoV-2. 521 522

In conclusion, we show that SARS-CoV-2-specific memory T cells remain detectable after one 523

year PSO and are capable of proliferating and generating IFN-γ, IL-2, and GzmB responses against 524 SARS-CoV-2 structural proteins, which will likely influence disease course during re-infection of 525 variants and may help explain superior responses to vaccines. Individual recovered from mild disease; highly responsive to the CD8 T cell epitope 10-mer ORF1ab-10 (TTDPSFLGRY). (C) Individual recovered from severe disease; highly responsive to the CD8 + T cell epitope 9-mer M128-6 (RNRFLYIIK). For the 15-mer M128, 9-mers M128-1 to M128-7 were used to find the minimal epitope. 

Protection of BNT162b2 Vaccine 548 Booster against Covid-19 in Israel

Kwong 552 JC, Canadian Immunization Research Network Provincial Collaborative Network I. 2021. 553 Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic 554 SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative 555 design study

Differential anti-S antibody titers in vaccinated residents during an outbreak of SARS-558

CoV-2 variant B.1.351 (beta) in an elderly nursing home

Infections, hospitalisations, and deaths averted via a nationwide vaccination 563 campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a 564 retrospective surveillance study

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca 568 vaccines on covid-19 related symptoms, hospital admissions, and mortality in older 569 adults in England: test negative case-control study

Effects of COVID-19 Vaccination Timing and Risk Prioritization on Mortality 572 Rates, United States

Group 577 CCT. 2020. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Sero-monitoring of 582 health care workers reveals complex relationships between common coronavirus 583 antibodies and SARS-CoV-2 severity

Antigen-Specific Adaptive Immunity to SARS-CoV-588 2 in Acute COVID-19 and Associations with Age and Disease Severity

Persistent cellular immunity to SARS-592 CoV-2 infection

SARS-CoV-2-specific T cell immunity in cases of 596 COVID-19 and SARS, and uninfected controls

Broad and strong memory CD4(+) 605 and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following 606 COVID-19

Immunological memory to 610 SARS-CoV-2 assessed for up to 8 months after infection

The time course of the immune 612 response to experimental coronavirus infection of man

Prior SARS-CoV-2 infection is associated 614 with protection against symptomatic reinfection

620 Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in 621 COVID-19 patients

Optimized determination of T cell epitope responses

Optimizing peptide matrices for identifying T-cell antigens

Systematic 629 Examination of Antigen-Specific Recall T Cell Responses to SARS-CoV-2 versus 630 Influenza Virus Reveals a Distinct Inflammatory Profile

Ex vivo 632 measurement of the cytotoxic capacity of human primary antigen-specific CD8 T cells

Granzyme B prevents aberrant IL-17 production and 636 intestinal pathogenicity in CD4(+) T cells

Kinetics of 638 influenza A virus infection in humans

CoV-2 viral kinetics and association with mortality in hospitalized 645 patients from the French COVID cohort

Regulation of interferon-gamma during innate and 647 adaptive immune responses

Secreting but Not Gamma Interferon-Secreting T Cells Are Associated with Reduced 653 Viral Reservoirs in Early HIV Infection

Comparison of the ELISPOT and 656 cytokine flow cytometry assays for the enumeration of antigen-specific T cells

SARS-CoV-2-reactive T cells in healthy donors and 663 patients with COVID-19

Clonal analysis of 668 immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2. 669

Vivo Killing Capacity of Cytotoxic T Cells Is Limited and Involves Dynamic 674 Interactions and T Cell Cooperativity

678 Identification and characterization of a SARS-CoV-2 specific CD8(+) T cell response 679 with immunodominant features

Unbiased 683 Screens Show CD8(+) T Cells of COVID-19 Patients Recognize Shared Epitopes in 684 SARS-CoV-2 that Largely Reside outside the Spike Protein

2021. 691 SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell 692 recognition

Gang 694 AO, Hadrup SR. 2021. SARS-CoV-2 genome-wide T cell epitope mapping reveals 695 immunodominance and substantial CD8(+) T cell activation in COVID-19 patients. Sci 696 Immunol 6

Broadly directed SARS-CoV-2-specific CD4+ T cell response includes frequently 700 detected peptide specificities within the membrane and nucleoprotein in patients with 701 acute and resolved COVID-19

CD8(+) T cells 706 specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with 707 selective seasonal coronaviruses

Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory 710 Syndrome Coronavirus 2

Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid 713 protein in SARS-recovered patients

Characterization of pre-existing 719 and induced SARS-CoV-2-specific CD8(+) T cells

Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-723 Reactive to Common Cold Coronaviruses

Engineering T cells specific for a dominant severe acute respiratory 726 syndrome coronavirus CD8 T cell epitope

SARS-CoV-2-specific T 732 cells are rapidly expanded for therapeutic use and target conserved regions of the 733 membrane protein

Designing a SARS-CoV-2 T-Cell-Inducing Vaccine 737 for High-Risk Patient Groups. Vaccines (Basel)

SARS-CoV-2 specific memory T cell epitopes identified in COVID-19-741 recovered subjects

CoV-2 T cell epitopes in unexposed humans

748 Immunoinformatics prediction of overlapping CD8(+) T-cell, IFN-gamma and IL-4 749 inducer CD4(+) T-cell and linear B-cell epitopes based vaccines against COVID-19 750 (SARS-CoV-2)

Highly conserved, non-human-like, and 753 cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and 754 validation

Nesburn 757 AB, Kuppermann BD, BenMohamed L. 2021. Genome-Wide B Cell, CD4(+), and 758 CD8(+) T Cell Epitopes That Are Highly Conserved between Human and Animal

Identified from SARS-CoV-2 as Targets for Preemptive Pan-Coronavirus 760 Vaccines

SARS-CoV-2 mRNA vaccines induce 762 broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63

Immunodominant T-cell epitopes from the SARS-CoV-2 spike antigen reveal robust pre-767 existing T-cell immunity in unexposed individuals

Highly functional virus-specific cellular 772 immune response in asymptomatic SARS-CoV-2 infection

Memory T 774 cell responses targeting the SARS coronavirus persist up to 11 years post-infection

Lack of peripheral memory B cell responses in recovered patients 778 with severe acute respiratory syndrome: a six-year follow-up study

Proteins Is Not Associated with Recovery in Critical COVID-19 Patients

HIV-specific cytolytic CD4 T cell 789 responses during acute HIV infection predict disease outcome

T cell responses to whole SARS coronavirus in humans

The ORF8 protein of SARS-CoV-2 mediates immune evasion 798 through down-regulating MHC-Iota

Severe obesity, increasing age and male sex are independently 801 associated with worse in-hospital outcomes, and higher in-hospital mortality

Risk factors for severity and 805 mortality in adult COVID-19 inpatients in Wuhan

Cross-reactive CD4(+) T cells enhance SARS-CoV-2 immune responses 812 upon infection and vaccination